BCI
MRNA icon

Brinker Capital Investments’s Moderna MRNA Stock Holding History

Brinker Capital Investments’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Sell
4,973
-30
-0.6% -$1.55K ﹤0.01% 1583
2026
Q1 		$254K Buy
+5,003
New +$233K ﹤0.01% 1733
2024
Q4 		– Sell
-3,661
Closed -$245K – 1882
2024
Q3 		$245K Buy
3,661
+1,443
+65% +$132K ﹤0.01% 1623
2024
Q2 		$263K Buy
+2,218
New +$281K ﹤0.01% 1509
2024
Q1 		– Sell
-2,538
Closed -$293K – 1726
2023
Q4 		$293K Sell
2,538
-1,939
-43% -$163K ﹤0.01% 1411
2023
Q3 		$462K Sell
4,477
-6,392
-59% -$713K 0.01% 1229
2023
Q2 		$1.32M Buy
10,869
+583
+6% +$77.8K 0.01% 830
2023
Q1 		$1.58M Buy
10,286
+1,757
+21% +$290K 0.02% 691
2022
Q4 		$1.53M Buy
8,529
+1,956
+30% +$320K 0.03% 580
2022
Q3 		$777K Buy
6,573
+3,666
+126% +$556K 0.02% 800
2022
Q2 		$415K Buy
2,907
+1,238
+74% +$177K 0.01% 1044
2022
Q1 		$288K Buy
1,669
+489
+41% +$82.3K ﹤0.01% 1237
2021
Q4 		$300K Buy
+1,180
New +$345K ﹤0.01% 1257

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Brinker Capital Investments's MRNA Position: Q2 2026 in Review

Brinker Capital Investments reduced its Moderna (MRNA) stake by 0.6% in Q2 2026, selling an estimated $1.55K and leaving 4,973 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #1583.

Brinker Capital Investments first reported a position in MRNA in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.58M in Q1 2023. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Brinker Capital Investments held 4,973 shares of Moderna worth $348K as of Q2 2026.
  • Brinker Capital Investments sold 30 Moderna shares in Q2 2026, an estimated $1.55K.
  • Moderna made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1583 holding.
  • Brinker Capital Investments first reported a position in Moderna in Q4 2021 and has held it in 13 quarters since.
  • Brinker Capital Investments's Moderna position peaked at $1.58M in Q1 2023.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.